Pulse Biosciences, Inc. (PLSE) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Pulse Biosciences, Inc. on October 10, 2025. The filing reports on late-breaking clinical study results from the Company's nPulse Cardiac Surgical System first-in-human feasibility study, presented at the 39th European Association for Cardio-Thoracic Surgery Annual Meeting.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on clinical trial progress and does not contain financial statements or updated financial metrics.
Material Changes and Clinical Results
The Company announced significant progress in its nPulse Cardiac Surgical System feasibility study:
- Study Scope: 44 patients have been treated by three investigators to date.
- Initial Cohort Evaluation: 24 patients had ablation effectiveness and durability evaluated via electroanatomical mapping approximately three months post-procedure.
- Acute Success: 100% of posterior box isolations were acutely successful in the high-dose cohort.
- Durability: Success rate of Pulmonary Vein Isolation (PVI) per vein at approximately 3 months was 94% (63 out of 67).
- Efficiency: Average total ablation time was 50 seconds with an average of 13 applications.
- Safety Profile: No reports of esophageal or phrenic nerve damage. No ablation-related severe or major adverse events were reported.
Guidance, Outlook, and Risks
The filing does not provide updated financial guidance, outlook, or specific risk factors beyond the inherent risks of clinical development. Management commentary is limited to the announcement of the positive clinical data and the incorporation of the press release as Exhibit 99.1.
Key Facts for Investor Verification
- Verify the full text of the press release (Exhibit 99.1) for detailed methodology and statistical significance of the 94% PVI success rate.
- Confirm the timeline for the next phase of the clinical study or regulatory submission plans.
- Review the Company's most recent 10-Q or 10-K for current cash runway and burn rate, as this 8-K contains no financial data.
- Monitor for any subsequent safety reports or adverse event disclosures as the study expands beyond the initial cohort.